On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and pediatric diabetic patients.
The subcutaneous medication is approved in a 3 milliliter, prefilled pen and a 10 milliliter, multiple-dose vial. Like Novolog, Sanofi-Aventis’ drug should be administered five to 10 minutes before a meal. Side effects include hypoglycemia, severe allergic reactions, hypokalemia, injection site reactions, itching, rash, lipodystrophy, weight gain and swelling.
Merilog is the third FDA-approved insulin biosimilar, joining two long-acting biosimilar products approved in 2021.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.